Assessing Novo Nordisk’s (NYSE:NVO) Valuation After Recent Share Price Swings

What Novo Nordisk’s Recent Performance Signals for Investors

Novo Nordisk (NYSE:NVO) has drawn fresh attention after a mixed run in its share performance, with a gain over the past month contrasting with weaker moves in the past 3 months and year to date.

For investors, this split picture raises practical questions about how to weigh the company’s current valuation against its recent total return record and its role in diabetes, obesity, and rare disease treatments.

See our latest analysis for Novo Nordisk.

At a share price of $40.93, Novo Nordisk’s recent 7 day share price return of 9.32% contrasts with a 30 day gain of 6.51% and a 90 day share price decline of 34.33%. The 1 year total shareholder return of 27.21% and 3 year total shareholder return of 47.68% sit alongside a 5 year total shareholder return of 19.04%. This combination suggests momentum has recently faded after a strong multi year run.

If this mix of gains and pullbacks has you reassessing where to put fresh capital, it can be useful to compare Novo Nordisk with other healthcare names benefiting from the rise of AI supported drug development using 35 healthcare AI stocks

With annual revenue growth of 3.70%, net income growth of 3.32% and a value score of 5, plus a cited intrinsic discount of 63.45%, is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 56.9% Undervalued

Compared with the last close at $40.93, the most followed narrative pegs Novo Nordisk’s fair value at $95, implying a deep valuation reset in the story.

Novo Nordisk, a global leader in diabetes and obesity treatments, is trading at a deep discount to both its historical multiples and intrinsic value. The ADR is now priced at $47.05, reflecting a normalized P/E ratio of just 13.4×, down from a five-year average closer to 25 to 30×.

Read the complete narrative.

Want to see how this $95 fair value comes together? The narrative leans heavily on earnings power, margin resilience, and a future profit multiple that assumes the GLP 1 engine keeps working in Novo Nordisk’s favor.

Result: Fair Value of $95 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this hinges on semaglutide remaining dominant, and on policy and pricing moves in the US not tightening further as pressure on drug costs escalates.

Find out about the key risks to this Novo Nordisk narrative.

Next Steps

Given the mix of optimism and concern running through this story, it makes sense to move quickly, review the full data, and form your own stance using 3 key rewards and 3 important warning signs

Looking for more investment ideas?

If you are weighing what to do next after assessing Novo Nordisk, it is worth lining up a few contrasting stock ideas so you are not relying on a single name.

• Target resilience first by checking companies highlighted in the 71 resilient stocks with low risk scores to see which businesses pair lower risk scores with steadier profiles.
• Hunt for quality at a discount using the 59 high quality undervalued stocks and compare how other stocks stack up on both fundamentals and pricing.
• Round out your watchlist with candidates from the screener containing 23 high quality undiscovered gems that combine solid financial traits with lower levels of existing market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com